BioCentury
ARTICLE | Company News

Neuro3d ending operations

October 11, 2006 1:13 AM UTC

CNS company Neuro3d (Mulhouse, France) is winding down its operations after phosphodiesterase-4 (PDE-4) inhibitor ND1251 for depression exhibited toxicity in Phase I testing and PDE-2 inhibitor ND7001 showed preclinical toxicity. Development of both products has been terminated. The company also said that although out-licensing efforts are ongoing for its lead compound, ocaperidone to treat schizophrenia, it has been unable to find a partner to date.

Neuro3d in-licensed ocaperidone from Johnson & Johnson (JNJ) in 2002. In 2005, the antagonist of the serotonin (5-HT2A) receptor and dopamine D2 receptor met the primary endpoints in two Phase II trials to treat schizophrenia. JNJ has not exercised its right to opt back in to develop and sell ocaperidone [[BioCentury, 4/18/2005, A10]]. ...